title: Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
abstract: BACKGROUND
  The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased osteoclastogenesis and osteoclast activity in bone. Here, we used a mixed osteolytic/osteoblastic murine model of bone-metastatic prostate cancer, RM1(BM), to determine how inhibiting osteolysis with ZOL affects the ability of these cells to establish metastases in bone, the integrity of the tumour-bearing bones and the survival of the tumour-bearing mice.
  
  
  METHODS
  The model involves intracardiac injection for arterial dissemination of the RM1(BM) cells in C57BL/6 mice. ZOL treatment was given via subcutaneous injections on days 0, 4, 8 and 12, at 20 and 100 µg/kg doses. Bone integrity was assessed by micro-computed tomography and histology with comparison to untreated mice. The osteoclast and osteoblast activity was determined by measuring serum tartrate-resistant acid phosphatase 5b (TRAP 5b) and osteocalcin, respectively. Mice were euthanased according to predetermined criteria and survival was assessed using Kaplan Meier plots.
  
  
  RESULTS
  Micro-CT and histological analysis showed that treatment of mice with ZOL from the day of intracardiac injection of RM1(BM) cells inhibited tumour-induced bone lysis, maintained bone volume and reduced the calcification of tumour-induced endochondral osteoid material. ZOL treatment also led to a decreased serum osteocalcin and TRAP 5b levels. Additionally, treated mice showed increased survival compared to vehicle treated controls. However, ZOL treatment did not inhibit the cells ability to metastasise to bone as the number of bone-metastases was similar in both treated and untreated mice.
  
  
  CONCLUSIONS
  ZOL treatment provided significant benefits for maintaining the integrity of tumour-bearing bones and increased the survival of tumour bearing mice, though it did not prevent establishment of bone-metastases in this model. From the mechanistic view, these observations confirm that tumour-induced bone lysis is not a requirement for establishment of these bone tumours.
authors: Prince of Wales Clinical School, Prince of Wales Hospital, Randwick, New South Wales, Australia.
authors: Tzong-Tyng
authors: TT
authors: Hung
authors: Jeffrey
authors: J
authors: Chan
authors: Pamela J
authors: PJ
authors: Russell
authors: Carl A
authors: CA
authors: Power
references: Stem Cells. 2006 Apr;24(4):986-91
references: 16293576
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s
references: 17062703
references: Int J Cancer. 2008 Nov 15;123(10):2267-78
references: 18729185
references: J Bone Miner Res. 2003 Mar;18(3):482-92
references: 12619933
references: J Clin Oncol. 2002 May 1;20(9):2353-9
references: 11981007
references: BMC Cancer. 2006 Jan 17;6:15
references: 16417633
references: Urology. 2010 Nov;76(5):1175-81
references: 21056263
references: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6
references: 11562486
references: Eur Urol. 2007 Nov;52(5):1381-7
references: 17321667
references: Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):143-57
references: 12909227
references: Bone. 2004 Apr;34(4):697-709
references: 15050901
references: Clin Exp Metastasis. 2007;24(3):169-78
references: 17440822
references: Prostate. 2009 Nov 1;69(15):1613-23
references: 19585491
references: Biotech Histochem. 1992 Nov;67(6):339-45
references: 1283340
references: Cancer Res. 2009 Apr 15;69(8):3433-42
references: 19351846
references: Clin Cancer Res. 2003 Jan;9(1):295-306
references: 12538482
references: Cancer Treat Rev. 2005;31 Suppl 3:1-8
references: 16225995
references: J Urol. 2008 Sep;180(3):1154-60
references: 18639279
references: Nature. 1996 Aug 1;382(6590):448-52
references: 8684484
references: J Orthop Res. 2003 Jan;21(1):62-72
references: 12507581
references: Curr Med Res Opin. 2011 Jan;27(1):55-62
references: 21083514
references: Clin Cancer Res. 2004 Jul 1;10(13):4559-67
references: 15240548
references: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):264-72
references: 17084550
references: Breast Cancer Res Treat. 2002 Oct;75(3):249-58
references: 12353814
references: J Bone Miner Res. 1998 Apr;13(4):581-9
references: 9556058
references: Br J Cancer. 2008 Jun 3;98(11):1753-8
references: 18506177
references: Blood. 2003 Sep 15;102(6):2310-1
references: 12959943
references: Prostate Cancer Prostatic Dis. 2005;8(3):253-9
references: 15999121